{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T06:43:48Z","timestamp":1783665828539,"version":"3.55.0"},"reference-count":41,"publisher":"Public Library of Science (PLoS)","issue":"4","license":[{"start":{"date-parts":[[2025,4,2]],"date-time":"2025-04-02T00:00:00Z","timestamp":1743552000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"\nBackground<\/jats:title>\nPeople living with HIV-2 are mainly found in West Africa and their identification and treatment have been impaired by diagnostic challenges and availability of effective antiretroviral treatment (ART). With the roll out of first line dolutegravir (DTG)-based regimen, the situation may have improved, emphasizing the need for data on long-term treatment outcomes and advanced HIV disease among ART-experienced people living with HIV-2.<\/jats:p>\n<\/jats:sec>\n\nMethod<\/jats:title>\nA prospective cohort was initiated in 2012 in C\u00f4te d\u2019Ivoire and Burkina Faso. All adult patients from C\u00f4te d\u2019Ivoire with an undetectable viral load, were included and followed up. HIV-2 viral load and CD4 counts were done during the routine follow-up visits and a detailed clinical assessment was done during the last follow up visit of the year 2018 corresponding to the censor date of the cohort. Outcomes were described as follow: in care (known alive and present during the last ART follow up visit), loss to follow-up (absent for more than 90 days and not reported dead), and dead (reported dead with a date of event). Advanced HIV disease followed WHO definition and virologic failure was define as viral load >\u200950 copies\/mm3<\/jats:sup>. The Kaplan-Meier curve was used to estimate mortality and Loss to follow-up probability.<\/jats:p>\n<\/jats:sec>\n\nResults<\/jats:title>\nAmong the 108 HIV-2 patients in virologic success in 2012, 95 agreed to participate and were enrolled in the \u201csuccess cohort\u201d. Their median age was 53 [47\u201360] years and all of them were receiving boosted-lopinavir-based ART regimen. Of the 95 participants, 65 (68.4%) remained in care, 20 (21.1%) were loss to follow-up and 10 (10.5%) were reported dead. The survival analysis retrieved a decreasing probability of remaining alive and in care over the time, moving from 90% to 80.7% and to 73.0% after 24, 48 and 72 months respectively. Overall, 36 (37.9%) patients presented with advanced HIV disease at their last visit, higher among those dead\/ loss to follow-up compared to those remaining in care (60.0% vs 27.7%; p-0.003).<\/jats:p>\n<\/jats:sec>\n\nConclusion<\/jats:title>\nHigh advanced HIV disease rate was found in HIV-2 patients, six years after an initial virologic success. This emphasizes the need to enable the one-stop-shop model that allow an early management of opportunistic infections while integrating non-communicable diseases services in HIV-2 care.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0317223","type":"journal-article","created":{"date-parts":[[2025,4,2]],"date-time":"2025-04-02T23:20:27Z","timestamp":1743636027000},"page":"e0317223","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":2,"title":["Mortality, loss to follow-up and advanced HIV disease following virologic success in West African HIV-2 patients"],"prefix":"10.1371","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-8972-8114","authenticated-orcid":true,"given":"Jean J.","family":"Koffi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon P.","family":"Boni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lion\u00e8le","family":"Mba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Bitty-Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annick G.","family":"Tchabert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank Y.","family":"Toure","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick A.","family":"Coffie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andre","family":"Inwoley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serge Paul","family":"Eholie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Didier K.","family":"Ekouevi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boris","family":"Tchounga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2025,4,2]]},"reference":[{"issue":"6","key":"pone.0317223.ref001","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1093\/cid\/ciq248","article-title":"Update on Human Immunodeficiency Virus (HIV)-2 infection","volume":"52","author":"OT Campbell-Yesufu","year":"2011","journal-title":"Clin Infect Dis"},{"issue":"5178","key":"pone.0317223.ref002","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1126\/science.7915856","article-title":"Reduced rate of disease development after HIV-2 infection as compared to HIV-1","volume":"265","author":"R Marlink","year":"1994","journal-title":"Science"},{"issue":"17","key":"pone.0317223.ref003","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1001\/jama.1993.03510170073033","article-title":"Epidemiology and transmission of HIV-2. Why there is no HIV-2 pandemic","volume":"270","author":"KM De Cock","year":"1993","journal-title":"JAMA"},{"issue":"7","key":"pone.0317223.ref004","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1086\/656284","article-title":"Mother-to-child transmission of HIV-2 infection from 1986 to 2007 in the ANRS french perinatal cohort EPF-CO1","volume":"51","author":"M Burgard","year":"2010","journal-title":"Clin Infect Dis"},{"issue":"18","key":"pone.0317223.ref005","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1097\/QAD.0b013e328315cdbc","article-title":"Lower levels of HIV-2 than HIV-1 in the female genital tract: Correlates and longitudinal assessment of viral shedding","volume":"22","author":"SE Hawes","year":"2008","journal-title":"AIDS"},{"issue":"18","key":"pone.0317223.ref006","doi-asserted-by":"crossref","first-page":"2593","DOI":"10.1097\/00002030-200312050-00006","article-title":"Factors associated with clinical progression in HIV-2 infected-patients: The French ANRS cohort","volume":"17","author":"S Matheron","year":"2003","journal-title":"AIDS"},{"issue":"5","key":"pone.0317223.ref007","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1097\/00002030-199005000-00010","article-title":"A comparison of HIV-1 and HIV-2 infections in hospitalized patients in Abidjan, C\u00f4te d\u2019Ivoire","volume":"4","author":"KM De Cock","year":"1990","journal-title":"AIDS"},{"issue":"22","key":"pone.0317223.ref008","doi-asserted-by":"crossref","first-page":"14410","DOI":"10.1073\/pnas.222366699","article-title":"Structure of HIV-2 reverse transcriptase at 2.35-\u00c5 resolution and the mechanism of resistance to non-nucleoside inhibitors","volume":"99","author":"J Ren","year":"2002","journal-title":"Proc Natl Acad Sci"},{"issue":"10","key":"pone.0317223.ref009","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1093\/cid\/cir123","article-title":"Immunovirological response to triple nucleotide reverse-transcriptase inhibitors and ritonavir-boosted protease inhibitors in treatment-naive HIV-2-infected patients: The ACHIEV2E collaboration study group","volume":"52","author":"A Benard","year":"2011","journal-title":"Clin Infect Dis"},{"key":"pone.0317223.ref010","first-page":"463704","article-title":"Antiretroviral therapy for HIV-2 Infection: Recommendations for management in low-resource settings","author":"K Peterson","year":"2011","journal-title":"AIDS Res Treat"},{"key":"pone.0317223.ref011","article-title":"British HIV Association guidelines for antiretroviral treatment of HIV-2-positive individuals 2010. 2010 - HIV Medicine - Wiley Online Library [Internet]","author":"Y Gilleece","year":"2010"},{"issue":"4","key":"pone.0317223.ref012","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1093\/cid\/ciy940","article-title":"A new mechanism of resistance of human immunodeficiency virus type 2 to integrase inhibitors: A 5-amino-acid insertion in the integrase C-terminal domain","volume":"69","author":"Q Le Hingrat","year":"2019","journal-title":"Clin Infect Dis"},{"issue":"5","key":"pone.0317223.ref013","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1093\/jac\/dkz007","article-title":"Clinical experience with integrase inhibitors in HIV-2-infected individuals in Spain","volume":"74","author":"S Requena","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"pone.0317223.ref014","volume-title":"Update of recommandations on first-and second-line antiretroviral regimens [Internet]. [cited 2022 Jun 13]","author":"WHO"},{"issue":"3","key":"pone.0317223.ref015","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1097\/01.aids.0000199829.57112.2f","article-title":"CD4 cell recovery in treated HIV-2-infected adults is lower than expected: Results from the french ANRS CO5 HIV-2 cohort","volume":"20","author":"S Matheron","year":"2006","journal-title":"AIDS"},{"key":"pone.0317223.ref016","volume-title":"DIRECTIVES-2015-DE-PEC-ADULTEENFANT-VF.pdf [Internet]"},{"issue":"8","key":"pone.0317223.ref017","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1097\/QAD.0000000000000244","article-title":"Genotypic resistance profiles of HIV-2-treated patients in West Africa","volume":"28","author":"C Charpentier","year":"2014","journal-title":"AIDS"},{"key":"pone.0317223.ref018","volume-title":"Directives 2015 de prises en charge des personnes vivant avec le VIH en C\u00f4te d\u2019Ivoire [Internet]"},{"key":"pone.0317223.ref019","first-page":"589817","article-title":"Loss to followup: a major challenge to successful implementation of prevention of mother-to-child transmission of HIV-1 programs in sub-saharan africa","author":"FW Kalembo","year":"2012","journal-title":"ISRN AIDS"},{"issue":"1","key":"pone.0317223.ref020","doi-asserted-by":"crossref","first-page":"23259582221143675","DOI":"10.1177\/23259582221143675","article-title":"Future of HIV2 and HIV2 1 infected patients treated with antiretrovirals followed at the day hospital HIV care unit from 2011 to 2015","volume":"21","author":"I Diallo","year":"2022","journal-title":"J Int Assoc Provid AIDS Care"},{"issue":"17","key":"pone.0317223.ref021","doi-asserted-by":"crossref","first-page":"2707","DOI":"10.1097\/QAD.0000000000001232","article-title":"Effect of sex and age on outcomes among HIV-2-infected patients starting antiretroviral therapy in West Africa","volume":"30","author":"BK Tchounga","year":"2016","journal-title":"AIDS"},{"issue":"8","key":"pone.0317223.ref022","doi-asserted-by":"crossref","first-page":"e0236460","DOI":"10.1371\/journal.pone.0236642","article-title":"Survival among antiretroviral-experienced HIV-2 patients experiencing virologic failure with drug resistance mutations in Cote d\u2019Ivoire West Africa","volume":"15","author":"B Tchounga","year":"2020","journal-title":"PLoS One"},{"issue":"1","key":"pone.0317223.ref023","first-page":"445","article-title":"Attrition and its predictors among adults receiving first-line antiretroviral therapy in Woldia Town public health facilities, Northeast Ethiopia: A retrospective cohort study","volume":"13","author":"D Dejen","year":"2021","journal-title":"HIV AIDS (Auckl)"},{"issue":"4","key":"pone.0317223.ref024","doi-asserted-by":"crossref","first-page":"e0217606","DOI":"10.1371\/journal.pone.0217606","article-title":"Determinants of loss to follow-up among HIV positive patients receiving antiretroviral therapy in a test and treat setting: A retrospective cohort study in Masaka, Uganda","volume":"15","author":"J Kiwanuka","year":"2020","journal-title":"PLoS One"},{"issue":"2","key":"pone.0317223.ref025","doi-asserted-by":"crossref","first-page":"296","DOI":"10.9745\/GHSP-D-20-00532","article-title":"Differentiated service delivery models for HIV treatment in malawi, south africa, and zambia: A landscape analysis","volume":"9","author":"A Huber","year":"2021","journal-title":"Glob Health Sci Pract"},{"issue":"4","key":"pone.0317223.ref026","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1007\/s11904-019-00454-5","article-title":"A Review of differentiated service delivery for HIV treatment: Effectiveness, mechanisms, targeting, and scale","volume":"16","author":"M Roy","year":"2019","journal-title":"Curr HIV\/AIDS Rep"},{"issue":"3","key":"pone.0317223.ref027","first-page":"280","article-title":"Twelve-month outcomes of community-based differentiated models of multimonth dispensing of ART among stable HIV-infected adults in Lesotho: A cluster-randomized noninferiority trial","volume":"85","author":"B Tukei","year":"2020","journal-title":"JAIDS"},{"issue":"2","key":"pone.0317223.ref028","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1097\/QAI.0000000000002333","article-title":"Outcomes of Three- Versus Six-Monthly Dispensing of Antiretroviral Treatment (ART) for Stable HIV Patients in Community ART Refill Groups: A Cluster-Randomized Trial in Zimbabwe","volume":"84","author":"G Fatti","year":"2020","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"1","key":"pone.0317223.ref029","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1186\/s12913-022-08065-4","article-title":"The acceptability of integrated healthcare services for HIV and non-communicable diseases: experiences from patients and healthcare workers in Tanzania","volume":"22","author":"EH Shayo","year":"2022","journal-title":"BMC Health Serv Res"},{"issue":"1","key":"pone.0317223.ref030","doi-asserted-by":"crossref","first-page":"21","DOI":"10.5430\/ijh.v1n1p21","article-title":"Integration of HIV\/AIDS and noncommunicable diseases in developing countries: rationale, policies and models","volume":"1","author":"T Haregu","year":"2015","journal-title":"Int J Healthcare"},{"key":"pone.0317223.ref031","doi-asserted-by":"crossref","DOI":"10.11604\/pamj.2016.25.40.8329","article-title":"High prevalence and excess mortality of late presenters among HIV-1, HIV-2 and HIV-1\/2 dually infected patients in guinea-bissau - a cohort study from west africa","volume":"25","author":"BL H\u00f8nge","year":"2016","journal-title":"Pan Afr Med J"},{"issue":"222","key":"pone.0317223.ref032","article-title":"Infection \u00e0 vih-2 au s\u00e9n\u00e9gal: \u00e9checs virologiques et r\u00e9sistances aux antir\u00e9troviraux (ARV)","volume":"33","author":"S Ba","year":"2019","journal-title":"Pan Afr Med J"},{"key":"pone.0317223.ref033","article-title":"Recommendations to reduce mortality and morbidity among people presenting with advanced HIV disease.","volume-title":"Guidelines for managing advanced HIV disease and rapid initiation of antiretroviral therapy [Internet]","author":"Organisation mondiale de la sant\u00e9","year":"2017"},{"issue":"15","key":"pone.0317223.ref034","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1097\/QAD.0000000000002627","article-title":"Advanced HIV disease in the botswana combination prevention project: Prevalence, risk factors, and outcomes","volume":"34","author":"R Lebelonyane","year":"2020","journal-title":"AIDS"},{"key":"pone.0317223.ref035","volume-title":"Traitement antir\u00e9troviral: lignes directrices pour la prise en charge du stade avanc\u00e9 de la maladie \u00e0 VIH et l\u2019initiation rapide du traitement antir\u00e9troviral: note d\u2019information [Internet]. Organisation mondiale de la Sant\u00e9; 2017 [cited 2023 Aug 22]. Report No.: WHO\/HIV\/2017.18","author":"Organisation mondiale de la Sant\u00e9"},{"key":"pone.0317223.ref036","volume-title":"Pr\u00e9vention de la tuberculose: de nouvelles recommandations pour sauver des millions de vies [Internet]. 2020 [cited 2023 Aug 22]","author":"Organisation mondiale de la sant\u00e9"},{"issue":"2","key":"pone.0317223.ref037","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.ijid.2020.11.192","article-title":"Coverage of isoniazid preventive therapy among people living with HIV; a retrospective cohort study in tanzania (2012-2016)","volume":"103","author":"W Maokola","year":"2021","journal-title":"Int J Infect Dis"},{"issue":"8","key":"pone.0317223.ref038","doi-asserted-by":"crossref","first-page":"e0010625","DOI":"10.1371\/journal.pntd.0010625","article-title":"Integrated healthcare approach can curb the increasing cases of cryptococcosis in Africa","volume":"16","author":"C Ibe","year":"2022","journal-title":"PLoS Negl Trop Dis"},{"key":"pone.0317223.ref039","volume-title":"Directives de l\u2019OMS pour la prise en charge de l\u2019infection \u00e0 VIH avanc\u00e9e et l\u2019initiation rapide du traitement antir\u00e9troviral - OMS [Internet]"},{"issue":"3","key":"pone.0317223.ref040","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1056\/NEJMoa1615822","article-title":"Enhanced prophylaxis plus antiretroviral therapy for advanced HIV infection in Africa","volume":"377","author":"J Hakim","year":"2017","journal-title":"N Engl J Med"},{"issue":"9983","key":"pone.0317223.ref041","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1016\/S0140-6736(15)60164-7","article-title":"Cryptococcal meningitis screening and community-based early adherence support in people with advanced HIV infection starting antiretroviral therapy in tanzania and zambia: An open-label, randomised controlled trial","volume":"385","author":"S Mfinanga","year":"2015","journal-title":"Lancet"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0317223","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,2]],"date-time":"2025-04-02T23:22:15Z","timestamp":1743636135000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0317223"}},"subtitle":[],"editor":[{"given":"Zewdu Gashu","family":"Dememew","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,4,2]]},"references-count":41,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,4,2]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0317223","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,2]]}}}